Jason Paul Steik, Chief Clinical Officer of Pennant Group, Inc., filed a Form 4 on November 19, 2026, disclosing the sale of 218 shares of common stock on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Jason Paul Steik, Chief Clinical Officer of Pennant Group, Inc.
  • Transaction: 218 shares of common stock disposed of (transaction code S) on November 17, 2026
  • Sale price: $37.147 per share
  • Remaining ownership: 14,888 shares of common stock held directly following the transaction
  • 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c)
  • Exchange and ticker: NASDAQ:PNTG

Pennant Group Chief Clinical Officer Reports Share Sale Under 10b5-1 Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 19, 2026, Jason Paul Steik, serving as Chief Clinical Officer of Pennant Group, Inc. (NASDAQ:PNTG), reported the disposal of 218 shares of the company's common stock. The transaction was dated November 17, 2026, and carried transaction code "S," indicating a sale. The reported per-share price was $37.147.

The filing indicates that the sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as noted by the checked box on the form. Following the reported transaction, Steik directly beneficially owned 14,888 shares of Pennant Group common stock, according to the filing. No derivative securities transactions were reported in Table II of the form.

The Form 4 was signed by Kirk Cheney as attorney in fact on November 19, 2026, the same date it was filed. No amendment date was listed, indicating this was not a correction to a previously filed form. The issuer address on record for Steik is 1675 E. Riverside Dr., Suite 150, Eagle, Idaho 83616.

What Was Disclosed

Pennant Group Chief Clinical Officer Jason Paul Steik disclosed a sale of 218 shares of common stock at $37.147 per share on November 17, 2026, under a Rule 10b5-1 plan, leaving him with direct beneficial ownership of 14,888 shares.